Physician Administers First U.S. Infusion of Newly Approved Thyroid Eye Disease Treatment
Raymond Douglas, MD, PhD, has administered the first U.S. infusion of LUMVOA™ (veligrotug-vvze), a new FDA-approved treatment for Thyroid Eye Disease.
Beverly Hills, Calif. – July 16, 2026 – Raymond Douglas, MD, PhD, a specialist in Thyroid Eye Disease (TED) and oculoplastic surgery, has administered the first infusion of LUMVOA™ (veligrotug-vvze) in the United States, following its recent FDA approval. The milestone positions Dr. Douglas and his practice at the forefront of TED treatment advancements.
LUMVOA, developed by Viridian Therapeutics, received FDA approval in late June 2026. It is the second drug approved for TED and is indicated for both active and chronic forms of the disease, offering specialists a new therapeutic option for a broader patient population. Previous treatments historically relied on corticosteroids, surgery, and limited medical interventions.
Thyroid eye disease is a rare autoimmune condition that can cause protruding eyeballs, double vision, pain, and in severe cases, vision loss. The availability of a second targeted medical therapy marks a significant development in managing the condition.
"LUMVOA's approval represents an important advance for physicians treating thyroid eye disease, particularly because it expands the conversation around medical management for both active and chronic TED," said Raymond Douglas. "Being first in the nation to infuse this therapy reflects my practice's commitment to bringing new, evidence-based treatment options to patients as quickly and responsibly as possible."
Dr. Douglas's practice focuses heavily on TED and provides advanced medical and surgical care. Their work aims to ensure patients have access to the latest therapeutic options.